{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:00:21Z","timestamp":1789390821793,"version":"build-2803163510"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T00:00:00Z","timestamp":1464307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T00:00:00Z","timestamp":1464307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2016.34","type":"journal-article","created":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T13:20:50Z","timestamp":1464355250000},"page":"e427-e427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience"],"prefix":"10.1038","volume":"6","author":[{"given":"K","family":"Begna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Abdelatif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Schwager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,27]]},"reference":[{"key":"BFbcj201634_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/00000421-199802000-00024","volume":"21","author":"I Brodsky","year":"1998","unstructured":"Brodsky I . Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET). Am J Clin Oncol 1998; 21: 105\u2013106.","journal-title":"Am J Clin Oncol"},{"key":"BFbcj201634_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/bjc.1981.150","volume":"44","author":"C Haanen","year":"1981","unstructured":"Haanen C, Peetermans N, Cauchie C, Michel J, Strijckmans P, Mathe G et al. Treatment of polycythemia vera by radiophosphorous or busulphan: a randomized trial. \"Leukemia and Hematosarcoma\" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). Br J Cancer 1981; 44: 75\u201380.","journal-title":"Br J Cancer"},{"key":"BFbcj201634_CR3","first-page":"132","volume":"23","author":"PD Berk","year":"1986","unstructured":"Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR . Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986; 23: 132\u2013143.","journal-title":"Semin Hematol"},{"key":"BFbcj201634_CR4","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1182\/blood.V82.2.398.398","volume":"82","author":"R Hehlmann","year":"1993","unstructured":"Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 1993; 82: 398\u2013407.","journal-title":"Blood"},{"key":"BFbcj201634_CR5","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1182\/blood-2004-09-3426","volume":"105","author":"G Finazzi","year":"2005","unstructured":"Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Cea F . Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005; 105: 2664\u20132670.","journal-title":"Blood"},{"key":"BFbcj201634_CR6","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","volume":"90","author":"Y Najean","year":"1997","unstructured":"Najean Y, Rain JD . Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997; 90: 3370\u20133377.","journal-title":"Blood"},{"key":"BFbcj201634_CR7","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.3324\/haematol.2013.087742","volume":"98","author":"ET Kuriakose","year":"2013","unstructured":"Kuriakose ET, Gjoni S, Wang YL, Baumann R, Jones AV, Cross NC . JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug. Haematologica 2013; 98: e135\u2013e137.","journal-title":"Haematologica"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201634.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201634","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201634.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T09:06:14Z","timestamp":1672823174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,27]]},"references-count":7,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5]]}},"alternative-id":["BFbcj201634"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2016.34","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,27]]},"assertion":[{"value":"27 May 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}